ELEVATION ONCOLOGY INC (ELEV) Stock Price, Quote, News and Overview
NASDAQ:ELEV - Nasdaq - US28623U1016 - Common Stock - Currency: USD
ELEV Quote, Performance and Key Statistics
0.3759
+0 (+1.05%)
The current stock price of ELEV is 0.3759 USD. In the past month the price increased by 44.52%. In the past year, price decreased by -89.62%.
ELEV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About ELEV
Company Profile
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
Company Info
ELEVATION ONCOLOGY INC
101 Federal Street, Suite 1900
Boston MASSACHUSETTS US
CEO: Shawn Leland
Employees: 29
Company Website: https://elevationoncology.com/
Investor Relations: http://investors.elevationoncology.com
Phone: 17163711125
ELEVATION ONCOLOGY INC / ELEV FAQ
What is the stock price of ELEVATION ONCOLOGY INC today?
The current stock price of ELEV is 0.3759 USD. The price increased by 1.05% in the last trading session.
What is the ticker symbol for ELEVATION ONCOLOGY INC stock?
The exchange symbol of ELEVATION ONCOLOGY INC is ELEV and it is listed on the Nasdaq exchange.
On which exchange is ELEV stock listed?
ELEV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ELEVATION ONCOLOGY INC stock?
14 analysts have analysed ELEV and the average price target is 2.09 USD. This implies a price increase of 456.26% is expected in the next year compared to the current price of 0.3759. Check the ELEVATION ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELEVATION ONCOLOGY INC worth?
ELEVATION ONCOLOGY INC (ELEV) has a market capitalization of 22.26M USD. This makes ELEV a Nano Cap stock.
How many employees does ELEVATION ONCOLOGY INC have?
ELEVATION ONCOLOGY INC (ELEV) currently has 29 employees.
What are the support and resistance levels for ELEVATION ONCOLOGY INC (ELEV) stock?
ELEVATION ONCOLOGY INC (ELEV) has a support level at 0.37 and a resistance level at 0.4. Check the full technical report for a detailed analysis of ELEV support and resistance levels.
Should I buy ELEVATION ONCOLOGY INC (ELEV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ELEV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ELEV, evaluating the profitability, health, valuation and growth aspects
- ELEVATION ONCOLOGY INC (ELEV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELEVATION ONCOLOGY INC (ELEV) Sales and EPS estimates to see what analysts future expectations are.
- ELEVATION ONCOLOGY INC (ELEV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELEVATION ONCOLOGY INC (ELEV) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELEVATION ONCOLOGY INC (ELEV) Stock Chart to make your own analysis
- ELEVATION ONCOLOGY INC (ELEV) Latest news and press-releases to stay up to date.
Does ELEVATION ONCOLOGY INC (ELEV) stock pay dividends?
ELEV does not pay a dividend.
When does ELEVATION ONCOLOGY INC (ELEV) report earnings?
ELEVATION ONCOLOGY INC (ELEV) will report earnings on 2025-05-01, before the market open.
What is the Price/Earnings (PE) ratio of ELEVATION ONCOLOGY INC (ELEV)?
ELEVATION ONCOLOGY INC (ELEV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
What is the Short Interest ratio of ELEVATION ONCOLOGY INC (ELEV) stock?
The outstanding short interest for ELEVATION ONCOLOGY INC (ELEV) is 16.81% of its float. Check the ownership tab for more information on the ELEV short interest.
ELEV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ELEV. When comparing the yearly performance of all stocks, ELEV is a bad performer in the overall market: 97.25% of all stocks are doing better.
ELEV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ELEV. The financial health of ELEV is average, but there are quite some concerns on its profitability.
ELEV Financial Highlights
Over the last trailing twelve months ELEV reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 47.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.52% | ||
| ROE | -74.11% | ||
| Debt/Equity | 0.52 |
ELEV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to ELEV. The Buy consensus is the average rating of analysts ratings from 14 analysts.